Cobalt radiation with or without low-dose cisplatin for treatment of canine naso-sinus carcinomas.
The objective of this study was to determine if low-dose cisplatin could be added safely to radiation therapy for the treatment of naso-sinus carcinomas in dogs. Thirty-one dogs were evaluated; 18 of these dogs received cobalt radiation in combination with low-dose cisplatin while 13 dogs received radiation alone. No difference was observed for acute or late radiation effects. Cisplatin was administered at a dosage of 7.5 mg/m2 20 min prior to every other radiation treatment. An initial dose of 10 mg/m2 was intended but toxicity (primarily azotemia) was unacceptable. Cisplatin was administered as prescribed in 12 of 18 dogs. Cisplatin was discontinued in 2 dogs because of azotemia. In the other 4 dogs cisplatin was not administered as prescribed because the dogs were withdrawn from treatment due to disease progression or radiation effects. There was no long-term renal disease in patients who developed azotemia. The overall median survival was 433 days with 4 (12.9%) dogs still alive at the completion of the study.
Nadeau
Marie-Eve
ME
University of Illinois Veterinary Teaching Hospital, Small Animal Clinic, Urbana, IL 61802, USA.
Kitchell
Barbara E
BE
Rooks
Robert L
RL
LaRue
Susan M
SM
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002140:California / Q000453:epidemiology; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D004285:Dogs; D004334:Drug Administration Schedule; D005260:Female; D008297:Male; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000662:veterinary*; D009367:Neoplasm Staging; D011996:Records / Q000662:veterinary; D012189:Retrospective Studies; D016019:Survival Analysis
D000970:Antineoplastic Agents; D002945:Cisplatin